Clinical Experience in the Randomized Phase 3 Sierra Trial: Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Conditioning Enables Hematopoietic Cell Transplantation with Successful Engraftment and Acceptable Safety in Patients with Active, Relapsed/Refractory AML Not Responding to Targeted Therapies

Boglarka Gyurkocza,John M Pagel,Johnnie J Orozco,Vijay Reddy,Hannah Choe,Mitchell Sabloff,Parameswaran Hari,Michael W Schuster,Mark R Litzow,Arjun Law,Mark S Berger,James M Foran,Rajneesh Nath,Partow Kebriaei,George L Chen,Benjamin Tomlinson,Stuart Seropian,Patrick Stiff,Koen Van Besien,Sunil Abhyankar,Jennifer Spross ,Nebu Koshy ,Margarida Magalhaes-Silverman ,M Lévy ,Zaid Al-Kadhimi ,Camille N Abboud ,Avinash Desai ,Hillard M Lazarus ,Sergío Giralt ,Katarzyna Jamieson

doi:10.1182/blood-2021-148497

Clinical Experience in the Randomized Phase 3 Sierra Trial: Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Conditioning Enables Hematopoietic Cell Transplantation with Successful Engraftment and Acceptable Safety in Patients with Active, Relapsed/Refractory AML Not Responding to Targeted Therapies

Boglarka Gyurkocza, John M Pagel + Show 28 more

Open Access

https://doi.org/10.1182/blood-2021-148497

Copy DOI

Journal: Blood	Publication Date: Nov 5, 2021
Citations: 9

Affiliation: Memorial Sloan Kettering Cancer Center, Swedish Medical Center, Fred Hutch Cancer Center, Actinium Pharmaceuticals (United States), The Ohio State University, Ottawa Hospital, University of Ottawa, Medical College of Wisconsin, Stony Brook University Hospital, Mayo Clinic, Princess Margaret Cancer Centre, University Health Network, Banner Health, The University of Texas MD Anderson Cancer Center, Roswell Park Cancer Institute, University Hospitals Seidman Cancer Center, Yale University, Loyola University Medical Center, Cornell University, University of Kansas Medical Center, Baylor University Medical Center, Texas Oncology, University of Nebraska Medical Center, Saint Louis Zoo, Washington University in St. Louis, University Hospitals of Cleveland, University of North Carolina at Chapel Hill

#Advisory Committees #Research Funding + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Clinical Experience in the Randomized Phase 3 Sierra Trial: Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Conditioning Enables Hematopoietic Cell Transplantation with Successful Engraftment and Acceptable Safety in Patients with Active, Relapsed/Refractory AML Not Responding to Targeted Therapies

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Blood

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.